Literature DB >> 6976058

Vestibular investigations in Meniere's disease.

J H Hulshof, E A Baarsma.   

Abstract

151 patients with unilateral Meniere's disease were investigated with a vestibular test battery in the interval between vertigo attacks, and the results were compared with those obtained in a control group. In 73.5% of the patients a caloric response reduction of the afflicted ear was observed. The mean caloric response reduction was 34.3%; a major response reduction or a total absence of the caloric response of the afflicted ear was rare. A correlation was found between the amount of caloric response reduction and the duration of the disease. Spontaneous nystagmus was found in 47% of the cases (mean value 3 degrees/sec) and a mainly direction fixed positional nystagmus in 78% (mean value 4.0 degrees/sec). No correlation was found between the mean hearing loss and the magnitude of caloric response reduction on the day of investigation.

Entities:  

Mesh:

Year:  1981        PMID: 6976058     DOI: 10.3109/00016488109133240

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  4 in total

1.  A longitudinal electrocochleographic study of a case of long-standing bilateral Lermoyez's syndrome.

Authors:  R Schoonhoven; P H Schmidt; J J Eggermont
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

2.  Evolution of caloric responses during and between the attacks of Meniere's disease.

Authors:  Sun-Uk Lee; Hyo-Jung Kim; Jeong-Yoon Choi; Ja-Won Koo; Ji-Soo Kim
Journal:  J Neurol       Date:  2021-02-21       Impact factor: 4.849

Review 3.  Interpretation and use of caloric testing.

Authors:  Denise Utsch Gonçalves; Lilian Felipe; Tânia Mara Assis Lima
Journal:  Braz J Otorhinolaryngol       Date:  2008 May-Jun

4.  Direction-fixed positional nystagmus following head-roll testing: how is it related with a vestibular pathology?

Authors:  Sertac Yetiser; Dilay Ince
Journal:  J Otol       Date:  2020-12-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.